TRICUSPID ATRESIA IN CHILDREN: CAUSES, RISK FACTORS, AND MANAGEMENT

Tricuspid atresia (TA) is a complex cyanotic congenital heart defect characterized by the complete absence of the tricuspid valve, which normally separates the right atrium from the right ventricle. This anomaly prevents direct blood flow from the right atrium to the right ventricle, making it obligatory for systemic venous return to cross an atrial septal defect (ASD) or patent foramen ovale (PFO) into the left atrium. Consequently, the right ventricle is typically hypoplastic, and the left ventricle becomes the systemic pumping chamber. TA represents approximately 1-3% of all congenital heart diseases and is a critical condition requiring early diagnosis and comprehensive management. Understanding its etiology, clinical presentation, diagnostic pathways, and management strategies is pivotal for improving patient outcomes.

Etiology of Tricuspid Atresia

The exact etiology of tricuspid atresia, like many congenital heart defects, is multifactorial, involving a complex interplay of genetic predispositions and environmental factors. However, the fundamental defect lies in abnormal embryological development.

Embryological Basis: During weeks 4 to 8 of gestation, the heart undergoes intricate septation and valve formation. Tricuspid atresia arises from a failure in the development of the tricuspid valve anlage or incomplete formation of the inferior interventricular septum in relation to the atrioventricular canal. This results in a fibrous or muscular impervious floor where the tricuspid valve should be, effectively creating an imperforate atrioventricular connection. The right ventricle, lacking its inlet, becomes hypoplastic to varying degrees, affecting its size and function depending on the presence and size of a ventricular septal defect (VSD). If a VSD is present, it allows for some blood flow into the right ventricle, enabling its development to a greater extent.

Genetic Factors: While TA is generally considered sporadic, certain genetic associations have been identified, though they are less common than in some other congenital heart defects.

• Chromosomal Anomalies: Rarely, TA has been linked to chromosomal abnormalities such as trisomy 21 (Down syndrome), trisomy 13, and trisomy 18. However, it is not a primary phenotypic characteristic of these syndromes.
• Syndromic Associations: TA can occur as part of complex syndromes, particularly heterotaxy syndromes (e.g., asplenia or polysplenia syndromes), which involve abnormal arrangement of thoracic and abdominal organs. These syndromes often present with multiple and severe cardiac malformations.
• Familial Recurrence: The risk of recurrence in subsequent pregnancies is low, suggesting a weak hereditary component for isolated TA, though genetic counseling may be considered for families with a history of congenital heart disease.

Environmental Factors: Exposure to certain environmental factors during critical periods of fetal development has been implicated in the etiology of congenital heart defects, including TA. However, a direct causal link for TA specifically is often challenging to establish definitively.

• Maternal Diabetes: Poorly controlled maternal diabetes is a known risk factor for various congenital anomalies, including cardiac defects.
• Teratogenic Exposures: Exposure to certain medications (e.g., retinoic acid derivatives, some anticonvulsants), maternal infections (e.g., rubella), or toxins during the first trimester can interfere with cardiogenesis.
• Maternal Phenylketonuria (PKU): Uncontrolled PKU in the mother can lead to an increased risk of congenital heart disease in the offspring.

In most cases, TA is believed to be a result of a complex interplay of subtle genetic predispositions interacting with one or more environmental triggers that disrupt normal cardiac embryogenesis. This multifactorial inheritance pattern makes precise prediction and prevention difficult.

Clinical Presentation of Tricuspid Atresia

The clinical presentation of tricuspid atresia varies significantly based on the associated cardiac anomalies, particularly the status of the pulmonary blood flow and the presence of a VSD and/or transposition of the great arteries (TGA). Symptoms typically manifest shortly after birth.

Key Pathophysiological Consequences:

• Obligatory Atrial Shunt: Systemic venous return from the right atrium must cross an ASD or a patent foramen ovale (PFO) into the left atrium to reach the systemic circulation.
• Mixing of Blood: This leads to mixing of desaturated systemic venous blood with oxygenated pulmonary venous blood in the left atrium and left ventricle.
• Pulmonary Blood Flow Dependence: Pulmonary blood flow is dependent on:
  • The presence and size of a VSD, allowing left ventricular blood to enter the hypoplastic right ventricle and then the pulmonary artery.
  • The patency of a patent ductus arteriosus (PDA) (if a VSD is absent or restrictive, or if there is pulmonary atresia).
  • The degree of pulmonary outflow obstruction (pulmonary stenosis or atresia).

Common Clinical Manifestations:

1. Cyanosis:

• Onset: Typically present at birth or within the first few days of life, and is the most common presenting symptom.
• Severity: Directly correlated with the degree of pulmonary blood flow.
  • Severe Cyanosis: Occurs when pulmonary blood flow is severely restricted (e.g., pulmonary atresia or severe pulmonary stenosis, restrictive VSD). These infants rely heavily on a PDA for pulmonary blood flow, and cyanosis worsens as the PDA closes.
  • Mild or Absent Cyanosis (early on): May occur if pulmonary blood flow is adequate or even excessive (e.g., large VSD with no pulmonary stenosis). In these cases, the primary symptom might be heart failure.
• Clinical Signs: Bluish discoloration of the skin, nail beds, and mucous membranes.

2. Tachypnea and Dyspnea:

• Onset: Develops as the infant struggles to maintain adequate oxygenation.
• Cause: Increased respiratory effort due to hypoxemia, or in cases of excessive pulmonary blood flow, due to pulmonary congestion and heart failure.

3. Poor Feeding and Failure to Thrive:

• Chronic hypoxemia and the increased metabolic demands of a compromised cardiovascular system lead to difficulty feeding, poor weight gain, and generalized lethargy.

4. Heart Murmurs and Auscultation Findings:

• Single Second Heart Sound (S2): Commonly heard due to the absence of the tricuspid valve and often an unappreciated or absent pulmonary valve closure sound.
• Murmurs: Highly variable depending on associated lesions:
  • Holosystolic Murmur: Suggests a VSD, often heard along the left sternal border. The intensity of this murmur can be inversely related to the degree of pulmonary stenosis (louder with less stenosis).
  • Continuous Murmur: If a PDA is present and providing pulmonary blood flow, a continuous murmur may be heard.
  • No Significant Murmur: Can occur if there is complete pulmonary atresia without a VSD or a very restrictive VSD.

5. Signs of Heart Failure (less common in neonates, more in specific subtypes):

• If pulmonary blood flow is excessive (e.g., large VSD without pulmonary stenosis): Infants may develop symptoms of congestive heart failure, including tachypnea, tachycardia, hepatomegaly, and poor feeding due to pulmonary overcirculation.
• If the ASD/PFO is restrictive: Systemic venous congestion can occur, leading to hepatomegaly and peripheral edema, although this is less common than signs related to pulmonary flow.

6. Delayed Presentation (Rare):

• In some rare instances, with a balanced pulmonary blood flow, the diagnosis might be delayed until infancy or early childhood, presenting with exertional dyspnea, fatigue, or cyanosis with activity. Chronic cyanosis can lead to clubbing and polycythemia.

Associated Anomalies (Crucial for Presentation): The specific associated lesions profoundly influence the clinical picture:

• Ventricular Septal Defect (VSD): Almost always present, allowing blood from the left ventricle to enter the hypoplastic right ventricle and then the pulmonary artery. Its size determines the amount of pulmonary blood flow from the left ventricle.
• Pulmonary Stenosis (PS) or Atresia (PA): Present in the majority of cases (approximately 70-80%). This restricts pulmonary blood flow, leading to increased cyanosis.
• Transposition of the Great Arteries (TGA): Occurs in about 30% of TA cases. The aorta arises from the right ventricle and the pulmonary artery from the left ventricle. This significantly alters the hemodynamics, where the PDA might be crucial for systemic blood flow, and the VSD for pulmonary blood flow.
• Patent Ductus Arteriosus (PDA): Essential for survival in patients with pulmonary atresia or severe pulmonary stenosis, as it provides the sole source of pulmonary blood flow from the aorta.

Early recognition of these symptoms and prompt evaluation are critical, as the natural history of untreated tricuspid atresia is very poor, with high mortality rates in the first year of life.

Diagnostic Workup for Tricuspid Atresia

A comprehensive diagnostic workup is essential for confirming tricuspid atresia, assessing its severity, identifying associated anomalies, and guiding management. This process often begins prenatally or immediately after birth.

1. Prenatal Diagnosis:

• Fetal Echocardiography: This is the gold standard for prenatal diagnosis of congenital heart disease. It can identify TA as early as the second trimester.
  • Key Findings: Absence of a discernible tricuspid valve apparatus; an imperforate membrane or fibrous tissue at the expected location of the tricuspid valve; a small, hypoplastic right ventricle; an enlarged left atrium and left ventricle; and evidence of an obligatory atrial shunt (ASD/PFO).
  • Associated Findings: Assessment of the great arteries (normal or TGA), presence and size of a VSD, and the pulmonary artery flow and size.
• Implications: Prenatal diagnosis allows for counseling of parents, planned delivery at a specialized center with pediatric cardiology and cardiac surgery capabilities, and early intervention immediately postpartum.

2. Postnatal Diagnosis:

• Physical Examination:
  • Observation: Presence and severity of cyanosis, tachypnea, and signs of respiratory distress.
  • Palpation: Assess for peripheral pulses (may be diminished in complex TGA), precordial activity (left ventricular impulse may be prominent). Hepatomegaly suggests systemic venous congestion or heart failure.
  • Auscultation: Single S2 is a classic finding. Murmurs vary (holosystolic for VSD, continuous for PDA).
• Pulse Oximetry Screening: A routine newborn screen that will detect hypoxemia and indicate the need for further cardiac evaluation.
• Chest X-ray (CXR):
  • Cardiac Silhouette: Can range from normal to enlarged, depending on the degree of pulmonary blood flow and ventricular hypertrophy.
  • Pulmonary Vascular Markings:
    • Decreased: Suggests pulmonary stenosis or atresia (classic for TA with reduced pulmonary flow).
    • Increased: Indicates pulmonary overcirculation (TA with large VSD and no pulmonary stenosis).
  • Right Atrial Enlargement: May be evident due to obstruction at the tricuspid valve level.
  • “Boot-shaped” Heart: Less common than in Tetralogy of Fallot, but can occur if pulmonary outflow is severely restricted.
• Electrocardiogram (ECG):
  • Left Axis Deviation (LAD): A highly characteristic and nearly pathognomonic finding, occurring in the majority of patients with TA. This is due to the single left ventricle driving the systemic circulation and superiorly oriented electrical forces.
  • Right Atrial Enlargement: Often manifests as tall, peaked P waves (P-pulmonale) in leads II, III, aVF, reflecting the increased volume and pressure in the right atrium.
  • Left Ventricular Hypertrophy (LVH): Evident as tall R waves in V5/V6 and deep S waves in V1/V2, consistent with the left ventricle functioning as the dominant and sole systemic pumping chamber.
  • Absence of Right Ventricular Hypertrophy (RVH): In contrast to many other cyanotic heart diseases, there is typically no RVH due to the hypoplastic nature of the right ventricle.
• Echocardiography (Transthoracic): This is the definitive diagnostic tool for postnatal confirmation and comprehensive anatomical and hemodynamic assessment.
  • 2D Imaging: Directly visualizes the absent tricuspid valve, the imperforate atrioventricular connection, the hypoplastic right ventricle, and the enlarged left atrium and left ventricle.
  • Doppler Studies:
    • Confirm the presence and direction of flow across the ASD/PFO (right-to-left shunt).
    • Assess the size and flow across the VSD.
    • Evaluate the extent of pulmonary stenosis or atresia and the patency and flow through a PDA.
    • Determine the relationship of the great arteries (normal or TGA).
    • Assess ventricular function, valve integrity, and gradients.
  • Color Doppler: Clearly depicts blood flow patterns and shunts.
• Cardiac Catheterization:
  • Diagnostic Use: While not typically required for primary diagnosis due to the efficacy of echocardiography, it may be used in select cases:
    • Pulmonary vascular resistance assessment before Fontan.
    • Clarification of complex anatomy not fully delineated by echo.
    • Assessment of collateral vessels.
  • Interventional Use:
    • Balloon Atrial Septostomy (BAS): Crucial if the ASD/PFO is restrictive, to enlarge the opening and improve interatrial mixing, relieving right atrial hypertension and enhancing systemic oxygenation. This is often a life-saving procedure in symptomatic neonates.
• Cardiac MRI/CT:
  • Role: Increasingly utilized in older children and adults with TA, particularly for detailed evaluation of pulmonary artery anatomy, collateral vessels, ventricular volumes and function, and aortic arch anomalies. It provides excellent spatial resolution without radiation (MRI) or with detailed anatomical mapping (CT). Useful for pre-surgical planning, especially before Fontan.

The timely and accurate diagnostic workup for tricuspid atresia is paramount, enabling prompt initiation of medical stabilization and planning for staged surgical palliation.

Management for Tricuspid Atresia

The management of tricuspid atresia is a complex, multi-stage process aimed at establishing a functional univentricular circulation. Since the right ventricle is incapable of pumping, the goal is to redirect systemic venous return to the pulmonary arteries passively, allowing the single left ventricle to pump only oxygenated blood to the body. This involves a series of palliative surgical procedures.

1. Initial Medical Stabilization (Neonatal Period): The immediate priorities are to ensure adequate systemic oxygenation and maintain stable hemodynamics.

• Prostaglandin E1 (PGE1) Infusion: This is often the first-line intervention for neonates presenting with severe cyanosis due to restricted pulmonary blood flow (e.g., pulmonary atresia or severe pulmonary stenosis). PGE1 keeps the patent ductus arteriosus (PDA) open, providing a vital source of blood flow to the pulmonary arteries. Dosage is typically initiated at 0.05-0.1 mcg/kg/min and titrated to effect.
• Oxygen Administration: Judicious use is critical. While oxygen may improve cyanosis by increasing pulmonary vasodilation, excessive oxygen can paradoxically decrease pulmonary vascular resistance and lead to pulmonary overcirculation (“pulmonary steal”) in patients with adequate or excessive pulmonary blood flow (large VSD without PS), potentially compromising systemic blood flow.
• Management of Acidosis/Hypoglycemia: Correct metabolic derangements that can further complicate cardiac function.
• Diuretics/Inotropes: If signs of congestive heart failure develop, diuretics (e.g., furosemide) and inotropes (e.g., dopamine, milrinone) may be used to improve cardiac output and manage fluid overload, particularly in patients with excessive pulmonary blood flow.
• Balloon Atrial Septostomy (BAS): If the atrial septal defect (ASD) or patent foramen ovale (PFO) is restrictive, impeding the mixing of systemic and pulmonary venous blood, an urgent BAS is performed. This interventional catheterization procedure involves passing a balloon catheter across the ASD/PFO and inflating it to tear the septum, creating a larger opening for interatrial shunting and relieving right atrial hypertension. This can significantly improve systemic oxygenation.

2. Surgical Management (Staged Palliative Repair): The surgical approach is typically a three-stage palliation, collectively creating a “univentricular repair.”

• Stage 1: Neonatal/Early Infancy (First few weeks of life) The choice of procedure depends on the balance of pulmonary blood flow:
  • If pulmonary blood flow is restricted (most common):
    • Modified Blalock-Taussig (BT) Shunt: A synthetic conduit is placed between a systemic artery (usually the subclavian artery) and the ipsilateral pulmonary artery. This provides a controlled and reliable source of pulmonary blood flow, alleviating cyanosis.
  • If pulmonary blood flow is excessive (less common, e.g., large VSD with no pulmonary stenosis):
    • Pulmonary Artery Banding (PAB): A band is placed around the main pulmonary artery to create a controlled stenosis, reducing excessive blood flow to the lungs. This prevents pulmonary hypertension, pulmonary vascular disease, and ventricular dysfunction from overcirculation.
  • Complex Cases (e.g., Tricuspid Atresia with Transposition of the Great Arteries and Aortic Arch Obstruction): These cases may require more complex procedures like the Norwood operation, which involves reconstruction of the aorta and creation of a systemic-to-pulmonary shunt.
• Stage 2: Bidirectional Glenn Shunt (BDG) / Hemi-Fontan (Typically 4-6 months of age) This procedure addresses the superior vena cava (SVC) drainage.
  • The superior vena cava, carrying deoxygenated blood from the upper body, is disconnected from the right atrium and directly anastomosed to the pulmonary artery.
  • This allows passive blood flow from the upper body directly to the lungs, bypassing the single ventricle.
  • The previously placed BT shunt is typically ligated as it is no longer needed and can lead to ventricular volume overload.
  • This reduces the volume load on the single ventricle and improves systemic oxygenation by directing a portion of venous return directly to the pulmonary circulation without ventricular pumping.
• Stage 3: Fontan Procedure (Total Cavopulmonary Connection) (Typically 2-4 years of age) This is the final stage, redirecting all systemic venous return directly to the pulmonary arteries.
  • The inferior vena cava (IVC), carrying deoxygenated blood from the lower body and abdominal organs, is connected to the pulmonary artery system. This can be achieved through:
    • Lateral Tunnel Fontan: An intra-atrial tunnel is created to direct IVC blood to the pulmonary artery.
    • Extracardiac Conduit Fontan: A synthetic tube (conduit) is placed outside the heart to connect the IVC to the pulmonary artery.
  • The Fontan circulation ensures that all systemic venous blood bypasses the single ventricle and flows passively through the lungs before returning to the left atrium. The single ventricle then functions solely as a systemic pump.
  • A fenestration (a small hole in the conduit or tunnel) may be created temporarily to decompress the Fontan circulation and improve cardiac output, especially in the immediate postoperative period, gradually closing over time or being closed later in a catheterization procedure.

3. Long-term Follow-up and Management: Patients who undergo Fontan completion require lifelong specialized cardiac care. While the Fontan procedure is palliative, not curative, it significantly improves survival and quality of life. However, patients are prone to various Fontan-associated complications:

• Ventricular Dysfunction: The single ventricle is prone to long-term failure due to chronic volume and pressure overload.
• Arrhythmias: Atrial and ventricular arrhythmias are common, requiring monitoring and management (antiarrhythmics, ablation, pacemakers).
• Thromboembolism: The low-flow, high-pressure environment in the Fontan circulation increases the risk of clot formation, necessitating lifelong anticoagulation.
• Protein-Losing Enteropathy (PLE): A serious complication where plasma proteins are lost into the gastrointestinal tract due to elevated central venous pressure.
• Plastic Bronchitis: Casting of the bronchial tree with lymphatic casts, also linked to lymphatic dysfunction and elevated Fontan pressures.
• Fontan-Associated Liver Disease (FALD): Chronic passive congestion of the liver can lead to fibrosis, cirrhosis, and hepatocellular carcinoma.
• Exercise Intolerance: Patients often have reduced exercise capacity compared to healthy individuals.
• Heart Transplantation: May be considered for end-stage Fontan failure or severe complications like intractable PLE.

Prognosis: The prognosis for tricuspid atresia has dramatically improved with advances in surgical techniques and postoperative care. While survival into adulthood is now common, these patients require continuous monitoring and management of their complex circulation. A multidisciplinary team approach involving pediatric cardiologists, cardiac surgeons, intensivists, and other specialists is crucial for optimal outcomes.

Conclusion

Tricuspid atresia represents a critical and challenging congenital heart defect demanding a sophisticated understanding of its underlying embryology, diverse clinical presentations, and intricate management strategies. From its origins in early cardiogenesis to the intricate staged surgical palliation, the journey for a patient with TA is complex. The evolution of diagnostic tools, particularly fetal and echocardiography, has enabled earlier and more accurate identification. Coupled with the development of sophisticated staged surgical procedures – from initial shunts or bands to the Bidirectional Glenn and ultimately the Fontan operation – the prognosis for individuals with TA has remarkably transformed. While these interventions offer a chance at life, they create a unique physiology that necessitates lifelong, vigilant follow-up to address the potential for late complications. Ultimately, a holistic, multidisciplinary approach, combining advanced medical stabilization, precise surgical timing, and comprehensive long-term care, remains paramount in optimizing the lives of those born with tricuspid atresia.

References

1. Anderson, R. H., & Baker, E. J. (2010). Paediatric Cardiology (3rd ed.). Churchill Livingstone. (Though an older edition, fundamental embryology and anatomy remain classic references).
2. Braunwald, E., Zipes, D. P., Libby, P., & Bonow, R. O. (Eds.). (2018). Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine (11th ed.). Elsevier. (Provides comprehensive cardiology information, including congenital heart disease chapters.)
3. Koffler, T. A., & Slesnick, T. C. (2017). Tricuspid Atresia. In D. J. Hagler, S. F. P. Cetta, & J. M. C. Feltes (Eds.), The Cardiac Catheterization Handbook (6th ed., pp. 583-596). Elsevier Saunders.
4. Marelli, A. J., Ionescu-Ittu, R., Mackie, A. S., Guo, L., Dendukuri, J., & Kaouache, M. (2014). Congenital Heart Disease in the Developing World: A Systematic Review. Heart, Lung and Circulation, 23(4), 304-309. (While not specific to TA, highlights global prevalence and diagnostic challenges for CHDs).
5. Park, M. K. (2014). Park’s Pediatric Cardiology for Practitioners (6th ed.). Elsevier Saunders. (An excellent resource for practical clinical aspects of pediatric cardiology, including detailed sections on specific congenital heart defects).
6. Penny, D. J., & Shekerdemian, L. S. (2020). Pediatric Cardiac Intensive Care (2nd ed.). Springer. (Focuses on the critical care management of neonates and children with complex congenital heart disease).
7. Srivastava, D. (2006). Molecular Congenital Heart Disease. Current Opinion in Cardiology, 21(1), 58-63. (Discusses genetic underpinnings of CHD).